Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Mod GRF 1-29

Sermorelin, Growth Hormone Releasing Hormone (1-29), hGRF(1-29)NH2

Quick Stats
Studies 227
Trials 47
Completed PHASE1 INTERVENTIONAL NCT02553603

The Effect of Growth Hormone Releasing Hormone on Cognitive Function in Individuals With Mild Cognitive Impairment

View on ClinicalTrials.gov Updated Dec 15, 2025

Brief Summary

This study is examining the effects of growth hormone releasing hormone (GHRH) on mild cognitive impairment (MCI). GHRH will be given at a dose of 1mg/day for 10 weeks to subjects with MCI as well as healthy controls.

Detailed Description

Subjects with MCI as well as healthy controls will be given GHRH at a dose of 1mg/day for 10 weeks. This study is designed to investigate the effects of GHRH on the following things: 1) cognitive function as measured by our neuropsychologist with a series of short tests; 2) brain activity as measured by fMRI 3) lean and fat mass of your body as measured by DEXA; 4) physical function as measured by a walking test.

Interventions

Name: Growth Hormone Releasing Hormone (GHRH)
Type: DRUG
Description: Growth Hormone Releasing Hormone (GHRH) 1mg/day for 10 weeks
Name: Placebo Growth Hormone Releasing Hormone
Type: DRUG
Description: Placebo GHRH to be given once daily for 10 weeks

Primary Outcomes

Measure: Cognitive Function measured by SLUMS
TimeFrame: 10 weeks
Description: Cognitive function at 10 weeks measured by the St Louis University Mental Status (SLUMS)
Measure: Brain Perfusion measured by fMRI
TimeFrame: 10 weeks
Description: Brain Perfusion at 10 week measured by MRI
Measure: Brain Morphology measured by MRI
TimeFrame: 10 weeks
Description: Brain Morphology at 10 weeks measured by MRI

Trial Information

NCT ID

NCT02553603

Status

Completed

Study Type

INTERVENTIONAL

Phases

PHASE1

Sponsor

The University of Texas Medical Branch, Galveston

Last Updated

December 15, 2025

Related Peptides